FDA Leadership’s “Blind Spots” Lead to a Surge in Medical Device and Drug Recalls

FDA Leadership’s “Blind Spots” Lead to a Surge in Medical Device and Drug Recalls by David Gortler, Pharm. D at Brownstone Institute Americans assume that when they pick up a prescription from their pharmacy, an FDA quality control professional has verified that the contents are manufactured to rigorous agency standards. Unfortunately,...

Läs hela artikeln hos källan.